<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:26:31Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:1513130" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:1513130</identifier><datestamp>2006-07-20</datestamp><setSpec>molneuro</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://dtd.nlm.nih.gov/ns/archiving/2.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://dtd.nlm.nih.gov/ns/archiving/2.3/ https://dtd.nlm.nih.gov/archiving/2.3/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Mol Neurodegener</journal-id>
      <journal-title>Molecular Neurodegeneration</journal-title>
      <issn pub-type="epub">1750-1326</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC1513130</article-id>
      <article-id pub-id-type="pmcid">PMC1513130</article-id>
      <article-id pub-id-type="pmc-uid">1513130</article-id>
      <article-id pub-id-type="pmid">16930449</article-id>
      <article-id pub-id-type="publisher-id">1750-1326-1-2</article-id>
      <article-id pub-id-type="pmid">16930449</article-id>
      <article-id pub-id-type="doi">10.1186/1750-1326-1-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Presenilin-dependent intramembrane cleavage of ephrin-B1</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" corresp="yes" contrib-type="author">
          <name>
            <surname>Tomita</surname>
            <given-names>Taisuke</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>taisuke@mol.f.u-tokyo.ac.jp</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>Tanaka</surname>
            <given-names>Sayaka</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>snow-peas@mh.point.ne.jp</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Morohashi</surname>
            <given-names>Yuichi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>Yuichi.Morohashi@manchester.ac.uk</email>
        </contrib>
        <contrib id="A4" corresp="yes" contrib-type="author">
          <name>
            <surname>Iwatsubo</surname>
            <given-names>Takeshi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>iwatsubo@mol.f.u-tokyo.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan</aff>
      <pub-date pub-type="collection">
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>6</month>
        <year>2006</year>
      </pub-date>
      <volume>1</volume>
      <fpage>2</fpage>
      <lpage>2</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.molecularneurodegeneration.com/content/1/1/2"/>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>3</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>6</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2006 Tomita et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2006</copyright-year>
        <copyright-holder>Tomita et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
          <!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Tomita
               Taisuke
               
               taisuke@mol.f.u-tokyo.ac.jp
            </dc:author><dc:title>
            Presenilin-dependent intramembrane cleavage of ephrin-B1
         </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Molecular Neurodegeneration 1(1): 2-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1750-1326(2006)1:1&#x0003c;2&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1750-1326</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>-->
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Presenilin-dependent Î³-secretase cleavage of several transmembrane proteins, including amyloid-Î² precursor protein and Notch, mediates the intramembrane proteolysis to liberate their intracellular domains that are involved in cellular signaling. Considering Î³-secretase inhibitors as therapeutics for Alzheimer's disease, understanding the physiologically and biologically important substrate for Î³-secretase activity in brains is emerging issue. To elucidate the molecular mechanism and physiological role of Î³-secretase, we screened candidate molecules for Î³-secretase substrates.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>We show that ephrin-B1, that participates in cell-cell repulsive and attractive signaling together with its Eph receptor, constitutively undergoes ectodomain shedding and that the residual membrane-tethered fragment is sequentially cleaved by Î³-secretase to release the intracellular domain. Furthermore, overexpression of membrane-tethered ephrin-B1 caused protrusion of numerous cellular processes consisted of F-actin, that required the preservation of the most C-terminal region of ephrin-B1. In contrast, soluble intracellular domain translocated into the nucleus and had no effect on cell morphology.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Our findings suggest that ephrin-B is a genuine substrate for Î³-secretase and regulates the cytoskeletal dynamics through intramembrane proteolysis.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Alzheimer disease (AD) is a neurodegenerative disorder characterized pathologically by neuronal loss in the cerebral cortex accompanied by the deposition of amyloid Î² peptides (AÎ²) as senile plaques. AÎ² is produced by sequential proteolytic cleavages of the amyloid-Î² precursor protein (APP) by a set of membrane-bound proteases termed Î²- and Î³-secretases. Î³-Secretase is an unusual aspartic protease that cleaves APP within the transmembrane domain (TMD) [<xref ref-type="bibr" rid="B1">1</xref>]. Presenilins (PS) are highly conserved polytopic transmembrane proteins that are mutated in a majority of pedigrees of early-onset familial Alzheimer's disease. PS represent the active site component of Î³-secretase, a multiprotein complex comprised of Nicastrin, APH-1 and PEN-2 [<xref ref-type="bibr" rid="B2">2</xref>]. FAD-linked mutations in PS genes cause an increase in the production of AÎ² ending at position 42, that most readily form amyloid deposits in AD brains, implicating the seminal role of Î³-secretase/PS complex in the pathogenesis of AD.</p>
      <p>It has been shown that a number of type I single-span membrane proteins are cleaved by Î³-secretase [<xref ref-type="bibr" rid="B3">3</xref>]. Although Î³-secretase is unable to cleave the full-length (FL) form of these substrates, the membrane-tethered C-terminal fragments (CTF) generated by ectodomain shedding are processed by Î³-secretase to liberate N-terminal small fragments and C-terminal intracellular domains (ICD) into luminal and cytoplasmic side, respectively. The liberated ICD translocates into the nucleus and participates in signal transduction (e.g., Notch [<xref ref-type="bibr" rid="B4">4</xref>]). Thus, the Î³-secretase-mediated intramembrane proteolysis is highlighted as a novel mode of proteolysis-dependent signal transduction utilizing ICD [<xref ref-type="bibr" rid="B5">5</xref>]. Recently it was reported that the administration of functional Î³-secretase inhibitors in rodents caused an alteration in lymphopoiesis and intestinal cell differentiation through inhibition of Notch signaling [<xref ref-type="bibr" rid="B1">1</xref>]. Thus, the understanding of the molecular mechanism of the unusual mode of intramembrane proteolysis is a critical problem for the development of APP-specific Î³-secretase inhibitors for the treatment of AD.</p>
      <p>Although the cleavage sites of some substrates have been identified, the amino acid sequences within the transmembrane domain that undergo Î³-secretase cleavage exhibit a loose homology. To elucidate the molecular mechanism and physiological role of Î³-secretase in brains, we screened candidate molecules for Î³-secretase substrates using several criteria. Here we identified ephrin-B1 as a novel substrate for Î³-secretase-mediated intramembrane proteolysis.</p>
    </sec>
    <sec>
      <title>Results</title>
      <sec>
        <title>Proteolytic processing of ephrin-B</title>
        <p>Although several transmembrane proteins are reported as a substrate for PS/Î³-secretase-dependent intramembrane cleavage, a low homology of the amino acid sequences of transmembrane domain (TMD) has been found among these substrates [<xref ref-type="bibr" rid="B5">5</xref>]. We searched the database for novel Î³-secretase substrates that suffice the characteristics of known substrates using following criteria: i) type I transmembrane protein, ii) carrying a receptor/ligand structure, iii) engaged in cell-cell interaction, iv) undergoes ectodomain shedding (or harboring a homologous sequence to other proteins undergoing shedding at juxtamembrane region) v) an accumulation of endogenous C-terminal fragment (CTF) in PS-depleted cells. We selected some candidate molecules and analyzed the membrane fractions from various cell lines including MEFs from <italic>Psen1</italic><sup>-/-</sup>/<italic>Psen2</italic><sup>-/- </sup>(DKO) mice [<xref ref-type="bibr" rid="B6">6</xref>] by immunoblotting using commercially available antibodies against the C-terminal region. We found that an antibody against ephrin-B probed ~14â17 kDa bands corresponding to the membrane-tethered CTF in various cell membranes, in addition to ~40â50 kDa bands representing the endogenous full-length (FL) protein, and that these ~14â17 kDa bands were accumulated in membranes from PS DKO MEF (Fig. <xref ref-type="fig" rid="F1">1A</xref>). We also detected ~14â17 kDa bands that reacted with an anti-ephrin-B antibody in membrane fractions of adult mouse organs (Fig. <xref ref-type="fig" rid="F1">1B</xref>). Moreover, treatment by a Î³-secretase inhibitor, DAPT, caused a concentration-dependent accumulation of endogenous ephrin-B-CTF in COS cells (Fig. <xref ref-type="fig" rid="F1">1C</xref>). Finally, the accumulation of ephrin-B CTF was abolished by the overexpression of PS1 in DKO cells (Fig. <xref ref-type="fig" rid="F1">1D</xref>). Taken together, these data raised the possibility that ephrin-B-CTF is processed by PS-dependent Î³-secretase under a physiological condition, in a similar manner to known substrates for Î³-secretase.</p>
        <fig position="float" id="F1">
          <label>Figure 1</label>
          <caption>
            <p><bold>Immunoblot analysis of endogenous ephrin-B CTFs</bold>. Membrane fractions from cultured cells (A) and mouse organs (B) were subjected to immunoblot analyses using anti-ephrin-B antibody. C) Immunoblot analysis of lysates from COS cells treated with a Î³-secretase inhibitor DAPT. D) Immunoblot analysis of lysates from DKO cells expressing PS1.</p>
          </caption>
          <graphic xlink:href="1750-1326-1-2-1"/>
        </fig>
        <p>Î³-Secretase cleaves membrane-tethered CTF within TMD to liberate N-terminal soluble peptides and C-terminal ICD after the processing by sheddase within the luminal region [<xref ref-type="bibr" rid="B3">3</xref>]. Treatment by phorbol esters has been reported to induce ectodomain shedding by activation of ADAMs (a disintegrin and metalloprotease) (e.g., tumor necrosis factor-Î± converting enzyme) or matrix metalloproteases (MMPs) [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Importantly, GPI-anchored ephrin-A2 is associated with TACE and cleaved upon binding with EphA receptor [<xref ref-type="bibr" rid="B9">9</xref>]. Consistent with the prediction above, overexpressed ephrin-B1 FL was cleaved to generate ~14â17 kDa CTF, that was increased by treatment with phorbol 12-myristate 13-acetate (PMA) and further augmented by preincubation with DAPT (Fig. <xref ref-type="fig" rid="F2">2A</xref>). Moreover, coincubation with GM6001, a specific MMP inhibitor, abolished the accumulation of ephrin-B-CTF, suggesting that ephrin-B FL is shed by matrix metalloprotease within the luminal region. However, ephrin-B-ICD, the final product of Î³-cleavage, was hardly detected even in lysates of PMA-treated ephrin-B-overexpressing cells. Several reports indicated that Î³-secretase-generated ICDs are hardly detected <italic>in vivo </italic>because of their short half-lives due to proteasomal degradation [<xref ref-type="bibr" rid="B3">3</xref>]. Consistent with this feature, treatment by epoxomicin, a potent irreversible proteasome inhibitor, caused an accumulation of ~10â12 kDa polypeptides (fig. <xref ref-type="fig" rid="F2">2B</xref>). These smaller bands disappeared upon treatment by DAPT and/or GM6001, suggesting that the generation of ~10â12 kDa bands is mediated by MMP and Î³-secretase activity. Intriguingly, coincubation with DAPT and epoxomicin caused a marked accumulation of ephrin-B-CTF, which was abolished by GM6001, indicating that a fraction of ephrin-B-CTF undergo proteasomal degradation. Finally, incubation of membrane fractions from COS cells at 37 degree caused <italic>de novo </italic>Î³-secretase-dependent generation of ~10â12 kDa bands in a similar manner to that of APP ICD (AICD) (Fig. <xref ref-type="fig" rid="F3">3A</xref>) [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. These ~10â12 kDa bands were never generated from membranes of mouse embryonic fibroblasts (MEF) lacking <italic>Psen1/Psen2 </italic>(DKO) (Fig. <xref ref-type="fig" rid="F3">3B</xref>). Taken together, these data suggest that endogenous ephrin-B FL (~40â50 kDa) is constitutively processed by MMP within luminal region to generate CTF (~14â17 kDa), subsequently cleaved by Î³-secretase and liberates ICD (~10â12 kDa), the latter being rapidly degraded by proteasome in cytoplasm.</p>
        <fig position="float" id="F2">
          <label>Figure 2</label>
          <caption>
            <p><bold>Analysis of proteolytic processing of ephrin-B1</bold>. A) Immunoblot analysis of COS cells overexpressing ephrin-B1 (<italic>arrows</italic>). ephrin-B1-CTF (<italic>arrowheads</italic>) was increased by DAPT and PMA treatment, whereas GM6001 completely diminished the ephrin-B1-CTF. B) Effect of protease inhibitors on endogenous ephrin-B CTF. Note that proteasome inhibition by epoxomicin caused an accumulation of CTF (<italic>arrowhead</italic>) and ICD (<italic>asterisk</italic>), that was abolished by GM6001 treatment.</p>
          </caption>
          <graphic xlink:href="1750-1326-1-2-2"/>
        </fig>
        <fig position="float" id="F3">
          <label>Figure 3</label>
          <caption>
            <p><bold>Cell-free Î³-secretase assay for ephrin-B1 cleavage</bold>. A) Cell-assay using membranes from mock- or ephrin-B1-transfected COS cells. Samples incubated at 4 degree (4), 37 degree (37) or 37 degree with DAPT (D) were analyzed by immunoblotting by anti-ephrin-B antibody (<italic>Upper panel</italic>). Same fractions without incubation were indicated as "C". ephrin-B1 FL, ephrin-B-CTF and <italic>de novo </italic>generated ICD were shown by <italic>black arrow, arrowhead </italic>and <italic>asterisk</italic>, respectively. Endogenous APP (<italic>Lower panel</italic>) C-terminal stubs (<italic>white arrowhead</italic>) were cleaved by Î³-secretase to generate AICD (<italic>double asterisks</italic>). B) Cell-free assay of membranes from wild-type MEF (MEFwt) and MEF lacking <italic>Psen1 </italic>and <italic>Psen2 </italic>(DKO). ephrin-B-CTF and <italic>de novo </italic>generated ICD were indicated by <italic>arrowhead </italic>and <italic>asterisk</italic>.</p>
          </caption>
          <graphic xlink:href="1750-1326-1-2-3"/>
        </fig>
      </sec>
      <sec>
        <title>PS-dependent Î³-secretase cleavage of ephrin-B1</title>
        <p>To further characterize the intramembrane proteolysis of ephrin-B by Î³-secretase, truncated forms of ephrin-B1 fused with myc/His tag at N and C terminus were analyzed (Fig. <xref ref-type="fig" rid="F4">4A</xref>). eB1ÎE, that corresponds to CTF of ephrin-B1 starting at Ser<sup>218 </sup>residue fused with a signal peptide, was expressed as a 20 kDa protein, and its protein level was increased by DAPT treatment, whereas no smaller bands were detected (Fig. <xref ref-type="fig" rid="F5">5A</xref>). However, the accumulation of a smaller ~17 kDa polypeptide was detected upon epoxomicin treatment, which was abolished by coincubation with DAPT. Furthermore, <italic>de novo </italic>Î³-secretase-dependent generation of ICD-like smaller peptides was detected in a cell-free Î³-secretase assay using membranes of cells transfected with eB1ÎE (Fig. <xref ref-type="fig" rid="F5">5B</xref>). Next we constructed a cDNA encoding eB1ICD, that corresponds to a predicted Î³-secretase product, starting at intramembranous Val<sup>260 </sup>residue, the latter being closest to the analogous cleavage site of the previously reported ICDs (e.g., Notch [<xref ref-type="bibr" rid="B12">12</xref>]), and C-terminally fused to a myc/His tag (Fig. <xref ref-type="fig" rid="F4">4A</xref>). eB1ICD was detected only after epoxomicin treatment, but not affected by DAPT (Fig. <xref ref-type="fig" rid="F5">5C</xref>). Thus, it seems reasonable to speculate that ICD of ephrin-B is constitutively and directly generated from truncated eB1ÎE by Î³-secretase-mediated cleavage, but is highly labile because of its liability to proteasomal degradation.</p>
        <fig position="float" id="F4">
          <label>Figure 4</label>
          <caption>
            <p><bold>Schematic depiction of ephrin-B1 derivatives used in this study</bold>. A) N-terminally truncated ephrin-B1 derivatives. B) C-terminally truncated eB1ÎE derivatives. Putative amino acid sequence recognized by sheddase is <italic>underlined</italic>. Transmembrane domain is shown in <italic>bold</italic>. PDZ domain binding region (YKV) and Myc/His tag are indicated by <italic>shaded box </italic>and <italic>oval</italic>, respectively. <italic>Numbers </italic>indicate the residues in ephrin-B1 FL protein.</p>
          </caption>
          <graphic xlink:href="1750-1326-1-2-4"/>
        </fig>
        <fig position="float" id="F5">
          <label>Figure 5</label>
          <caption>
            <p><bold>Proteolytic processing of overexpressed ephrin-B1 derivatives</bold>. A) Proteasome and Î³-secretase inhibitor ("epo" and "DAPT", respectively) treatments on cells expressing eB1ÎE (<italic>black arrowhead</italic>). Proteolytically-generated ICD was shown by <italic>asterisk</italic>. DAPT inhibited the processing of eB1ÎE as well as endogenous APP (accumulation of C-terminal stub, <italic>white arrowhead </italic>in <italic>lower panel</italic>). B) Cell-free assay using COS membrane expressing eB1ÎE. <italic>de novo </italic>generated ICDs from eB1ÎE (<italic>black arrowhead</italic>) and APP C-terminal stub (<italic>white arrowhead</italic>) were indicated by <italic>asterisk </italic>and <italic>double asterisks</italic>, respectively. C) Inhibitor treatments (same as <italic>A</italic>) on cells expressing eB1ICD (<italic>asterisk</italic>). Accumulation of C-terminal stub (<italic>white arrowhead</italic>) by DAPT was shown at <italic>lower panel</italic>.</p>
          </caption>
          <graphic xlink:href="1750-1326-1-2-5"/>
        </fig>
        <p>Truncated ErbB-4 receptor tyrosine kinase is a direct substrate for Î³-secretase activity. PDZ domain binding motif at C terminus of ErbB-4 is suggested to be required for the intramembrane proteolysis [<xref ref-type="bibr" rid="B13">13</xref>]. Ephrin-B1 also harbors a PDZ domain binding motif consisting of Tyr-Lys-Val residues, that is thought to be crucial for the localization and function of ephrin-B1 through protein-protein interaction [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Furthermore, conserved tyrosines that are phosphorylated in response to stimulation by their ligands (i.e., EphB receptors) play an important role(s) in reverse signaling through phosphotyrosine-binding proteins [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. To examine the role of these functional motifs at C terminus of ephrin-B1 in Î³-secretase-mediated cleavage, we generated a series of C-terminally truncated eB1ÎE cDNAs: eB1ÎEÎtag that corresponds to ephrin-B-CTF without C-terminal myc/His tag, eB1ÎEÎtagÎYKV that lacks the tag as well as the PDZ domain binding motif, and eB1ÎEÎ34 that is deleted at the C-terminal 34 amino acids including all conserved tyrosines and fused with a C-terminal tag (Fig. <xref ref-type="fig" rid="F4">4B</xref>). Cell free assay using membrane fractions from transfected cells revealed that all the C-terminally modified eB1ÎE derivatives were cleaved by Î³-secretase to generate ICD-like peptides (Fig. <xref ref-type="fig" rid="F6">6</xref>). These data suggest that these protein-protein interaction motifs at the C terminus of ephrin-B1 are dispensable for the Î³-secretase-mediated proteolysis.</p>
        <fig position="float" id="F6">
          <label>Figure 6</label>
          <caption>
            <p><bold>Proteolytic processing of overexpressed eB1ÎE derivatives</bold>. Cell-free assay using COS membranes expressing eB1ÎEÎtag (left), eB1ÎEÎtagÎYKV (middle) and eB1ÎEÎ34 (right). Antibodies used were indicated below the panels. All derivatives (<italic>arrowheads</italic>) were cleaved to generate ICD-like peptides (<italic>asterisks</italic>) by Î³-secretase activity.</p>
          </caption>
          <graphic xlink:href="1750-1326-1-2-6"/>
        </fig>
        <p>Î³-Secretase cleavage generates ICDs that in turn translocate into the nucleus mediated by the nuclear localization signals (NLS) and/or binding proteins [<xref ref-type="bibr" rid="B12">12</xref>]. Several ICDs are shown to form transcriptionally active complex to facilitate the transcription of downstream genes (e.g., AICD, NICD, CD44ICD) [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. While there is no apparent canonical NLS in the cytoplasmic domain of ephrin-B, a basic amino acid cluster is located adjacent to the cytosolic face. As the basic amino acid cluster is known to function as NLS, we examined the fractionation analysis of cell lysates transfected with eB1ICD or eB1ICDÎNLS starting at Thr<sup>273 </sup>residue (Fig. <xref ref-type="fig" rid="F4">4A</xref>). eB1ICD polypeptides accumulated in the Triton X-100-insoluble fraction containing lamin A/C, whereas eB1ICDÎNLS was detected only in soluble fraction (Fig. <xref ref-type="fig" rid="F7">7A</xref>). Immunofluorescence analysis revealed that eB1ICD was chiefly localized within nucleus as well as in the cytoplasmic region, whereas the immunoreactivity of eB1ICDÎNLS was limited to the cytoplasm (Fig. <xref ref-type="fig" rid="F7">7C,D</xref>). In contrast, eB1ÎE localized at cell membranes including Golgi area (Fig. <xref ref-type="fig" rid="F7">7B</xref>). These data suggest that ICD of ephrin-B enters the nucleus utilizing the basic amino acid cluster at the juxtamembrane region as NLS. Collectively, our findings suggest that ephrin-B1 is a genuine Î³-secretase substrate, similarly to other authentic substrates like Notch.</p>
        <fig position="float" id="F7">
          <label>Figure 7</label>
          <caption>
            <p><bold>eB1ICD translocated into the nucleus</bold>. A) Immunoblot analysis of total (input), Triton-soluble (sup) or -insoluble (ppt) lysates from COS cells expressing eB1ICD (<italic>arrow</italic>) or eB1ICDÎNLS (<italic>arrowhead</italic>) using anti-myc (<italic>upper panel</italic>) or anti-lamin A/C (<italic>lower panel</italic>). B), C) and D) were the representative results of immunocytochemical analysis of COS cells expressing eB1ÎE, eB1ICD and eB1ICDÎNLS, respectively, using anti-myc antibody. Nucleus and golgi area were indicated by <italic>arrows </italic>and <italic>arrowhead</italic>, respectively.</p>
          </caption>
          <graphic xlink:href="1750-1326-1-2-7"/>
        </fig>
      </sec>
      <sec>
        <title>Membrane-attached truncated ephrin-B1 induced numerous cellular protrusions</title>
        <p>Ephrin-B is involved in the cell-cell contact-mediated signaling in collaboration with Eph receptors (e.g., cell migration and repulsion, neuritogenesis, angiogenesis) [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Recent data implicated ephrin-B in the morphogenesis of cells by regulation of actin dynamics through its phosphorylation and binding of partner proteins in cytoplasmic region [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. To characterize the functional impact of Î³-secretase-mediated cleavage in the ephrin-B1 signaling with reference to actin polymerization, we analyzed the morphology of COS cells transfected with ephrin-B1 derivatives. Intriguingly, several filopodia-like cellular processes that were highly enriched in actin filaments protruded from cells transfected with eB1ÎE (Fig. <xref ref-type="fig" rid="F8">8</xref>). The total length of cellular processes was increased by DAPT treatment (1.4 fold, p &lt; 0.05). In contrast, overexpression of eB1ICD did not elicit cellular protrusions (Fig. <xref ref-type="fig" rid="F7">7C</xref>). Importantly, eB1ÎEÎ34 also did not enhance the generation of cellular protrusions, suggesting that the most C-terminal region of ephrin-B that encompasses conserved tyrosines is indispensable for the induction of actin polymerization. These data suggest that eB1ÎE regulates the actin dynamics of subplasmalemmal domain, that is negatively regulated by the Î³-secretase activity-mediated cleavage.</p>
        <fig position="float" id="F8">
          <label>Figure 8</label>
          <caption>
            <p><bold>Immunocytochemical analysis of COS cells expressing eB1ÎE and eB1ÎEÎ34</bold>. COS cells were transfected with mock (A, E), eB1ÎE (B, C, F, G) or eB1ÎEÎ34 (D, H) and treated with DMSO (A-D) or DAPT (E-H). Fixed cells were probed with anti-myc (Green) and Rhodamin-Phalloidin (Red) for eB1ÎE and F-actin, respectively.</p>
          </caption>
          <graphic xlink:href="1750-1326-1-2-8"/>
        </fig>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Ephrin-B is a transmembrane protein that is implicated in bidirectional intercellular signaling in cooperation with its cognate receptor tyrosine kinase, Eph receptor [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Eph-ephrin binding induces the "forward signaling" through activation of the tyrosine kinase domain of Eph receptor. Moreover, ephrins also act as a receptor for Eph and recruit signaling into the host cell, which is referred to as the "reverse signaling". The cytoplasmic domain of ephrin-B ligands, that contains conserved tyrosine residues, mediates the phosphorylation-dependent and -independent reverse signaling, in cooperation with its binding proteins in FL form. Here, we show that ephrin-B is endoproteolyzed by metalloprotease (e.g., MMP) and then by Î³-secretase. We also found that N-terminally truncated ephrin-B2 also is the substrate for Î³-secretase (data not shown), suggesting that this proteolytic process is a common metabolic pathway for ephrin-B family proteins. Finally, membrane-tethered cytoplasmic domain of ephrin-B1 facilitated the formation of cellular protrusions enriched in polymerized actin, that is negatively regulated by Î³-secretase activity. The liberated ICD translocated into the nucleus. Our findings suggest that ephrin-B-mediated proteolysis-dependent signaling is regulated by the Î³-secretase activity.</p>
      <p>Several transmembrane proteins including kinase-type receptors are now known to undergo Î³-secretase cleavage after ectodomain shedding [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. We screened novel substrates of Î³-secretase using several criteria that are common to known substrates. Although the proteolytic processing of ephrin-B has not been reported, ephrin-A2, GPI-anchored type ephrin ligand, is cleaved by ADAM10/Kuzbanian upon activation by its cognate receptor, and this process is implicated in Eph-ephrin-A mediated axonal repulsion [<xref ref-type="bibr" rid="B9">9</xref>]. Our finding that ephrin-B is shed by metalloprotease suggest that Eph-ephrin-B interaction-mediated repulsion might also be regulated by proteolysis, in a similar manner to Notch [<xref ref-type="bibr" rid="B3">3</xref>]. However, recent reports showed that ephrin-B-mediated repulsion is regulated by trans-endocytosis after engagement with EphB receptor [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Furthermore, we observed that treatment of ephrin-B expressing cells with clustered EphB2 fusion protein had no effect on shedding as well as Î³-secretase-mediated cleavage of ephrin-B (data not shown). We also found that ephrin-B stub undergoes Î³-secretase-dependent intramembrane cleavage independently of its cytoplasmic C terminus, that contains a PDZ domain binding motif and conserved tyrosines. These findings suggest that Î³-secretase cleavage of ephrin-B is not regulated by a protein-protein interaction within its C-terminal region. These data also indicate that the proteolytic processing of ephrin-B represents a constitutive signaling or metabolic pathway, that may be independent of the interaction with EphB2 receptor in COS cells. However, it has been shown that ephrin-B can interact with other EphB receptors including EphA4. Further characterization using a complete set of Eph receptors and/or cell lines is needed for the elucidation of the precise role of proteolytic processing of ephrin-B in its signaling.</p>
      <p>To date, functions of Î³-secretase-generated ICD as transcriptional activator (i.e., Notch, APP, CD44) or repressor (i.e., Jagged, N-cadherin) within nucleus have been reported [<xref ref-type="bibr" rid="B3">3</xref>]. We found that proteolytically generated eB1ICD, that is highly labile, localizes to the nucleus. Moreover, deletion of the acidic amino acid stretch located at the cytosolic face diminished the nuclear localization of this intracellular fragment, inferring its role as a nuclear transcriptional regulator. Although eB1ICD lacks known transactivation domain, intracellular domains of a subset of Î³-secretase substrates interact with co-transcriptional activators after cleavage to facilitate nuclear translocation and/or transcriptional regulation (i.e, RBPJk for Notch [<xref ref-type="bibr" rid="B21">21</xref>], Fe65 for APP [<xref ref-type="bibr" rid="B22">22</xref>], YAP for ErbB-4 [<xref ref-type="bibr" rid="B23">23</xref>]). Further proteomic and genetic approach will be needed to clarify if eB1ICD regulates gene transcription.</p>
      <p>Membrane-tethered eB1ÎE induced protrusion of a numerous actin-rich cellular processes. Most importantly, DAPT treatment increased the total length of these protrusions induced by expression of eB1ÎE. From these data, it is reasonable to speculate that the ephrin-B1-stub after ectodomain shedding may gain an activity to promote actin polymerization, that is subsequently down-regulated by Î³-secretase-mediated cleavage. It is well known that Eph-ephrin-B signaling controls cell motility and adhesion through actin polymerization/depolymerization [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Furthermore, Eph-ephrin-B interaction mediates trans-endocytosis/retraction locally at contact sites between receptor cells and ligand cells, in a manner dependent on actin polymerization by Rac-signaling in receptor cells [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. Several actin binding/regulating proteins (e.g., Grb4) were implicated in the regulation of actin dynamics through association with phospho-tyrosines in ephrin-B ICD [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. Consistent with this, eB1ÎEÎ34, that lacks the Grb4-binding region, failed to promote protrusion of processes, and DAPT treatment without overexpression of eB1ÎE had no effect on cellular morphology. Intriguingly, genetic analysis revealed that several mutations in human ephrin-B1 gene are linked to familial and sporadic forms of craniofrontonasal syndrome (CFNS) [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. As ephrin-B1 knockout mice showed similar defects in skeletal patterning [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>], these CFNS-linked mutations are most likely leads to a loss-of-function of ephrin-B1. Of note, some CFNS-linked mutations cause a frameshift at the C terminus resulting in a loss of Grb4 binding site of ephrin-B1 [<xref ref-type="bibr" rid="B31">31</xref>]. Thus, the most C-terminal region of ephrin-B1 is indispensable for ephrin-B signaling, to which Î³-secretase activity might act as a negative regulator. This negative regulation of ephrin-B signaling mediated by Î³-secretase activity is very similar to what has been recently reported for deleted in colorectal cancer (DCC) in synaptic function [<xref ref-type="bibr" rid="B32">32</xref>].</p>
      <p>While several transmembrane proteins are reported as substrate for Î³-secretase [<xref ref-type="bibr" rid="B5">5</xref>], little information is available for the physiological significance <italic>in vivo </italic>of the intramembrane cleavage of these substrates other than Notch [<xref ref-type="bibr" rid="B4">4</xref>]. However, considering the fact that Eph-ephrin-B signaling shows functional synergy with Notch-Delta/Jagged signaling in somitegenesis [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>] and vasoculogenesis [<xref ref-type="bibr" rid="B35">35</xref>], Î³-secretase might be an important signaling component in these bi-directional signaling at multiple points. Our findings on the proteolytic processing of ephrin-B provide information about adverse side effects of Î³-secretase inhibitors for the treatment of Alzheimer disease, as well as a novel direction for understanding the molecular mechanism of Eph-ephrin-B signaling.</p>
    </sec>
    <sec sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec>
        <title>Construction of expression plasmid</title>
        <p>A full-length cDNA encoding human ephrin-B1 was subcloned into a pcDNA3.1/Hyg vector (Invitrogen) from I.M.A.G.E clone (clone ID 3867060) (Invitrogen). cDNAs encoding eB1ÎE, eB1ÎEÎtag, eB1ÎEÎYKV, eB1ÎEÎ34, eB1ICD and eB1ICDÎNLS were amplified by PCR using following primer pairs: 5'-AGCTTGAGTGGCCCAGGTGCA-3' as a sense primer and 5'-GAATCCGAGACCTTGTAGTAGAT-3' as an antisense primer for eB1ÎE, 5'-TACTACAAGGTCTGATCGGATCCAAGCTTGTGTGGTGGAATTCTG-3' as a sense primer and 5'-CAGAATTCCACCACACAAGCTTGGATCCGATCAGACCTTGTAGTA-3' as an antisense primer for eB1ÎEÎtag, 5'-GCGAACATCTACTGATCGGATCCAAGCTTGTGTGGTGGAATTCTG-3' as a sense primer and 5'-CAGAATTCCACCACACAAGCTTGGATCCGATCAGTAGATGTTCGC-3' as an antisense primer for eB1ÎEÎYKV, 5'-CCCAAGCTTGAGTGGCCCAGGTGCA-3' as a sense primer and 5'-GGGGGATCCGAGTTGTTCTCTGTAGT-3' as an antisense primer for eB1ÎEÎ34, 5'-GGTACCACCATGGTCCTACTACTG-3' as a sense primer and 5'-GGATCCGACCTTGTAGTAGAT-3' as an antisense primer for eB1ICD, 5'-CCCGGTACCACCATGACACAGCAGCGGGCG-3' as a sense primer and 5'-GGGGGATCCGACCTTGTAGTAGAT-3' as an antisense primer for eB1ICDÎNLS.</p>
      </sec>
      <sec>
        <title>Cell culture, transfection and retroviral infection</title>
        <p>Cell lines including SV40-transformed mouse embryonic fibroblasts (MEF) derived from wild-type (wt) or <italic>PSen1<sup>-/-</sup></italic><italic>PSen2</italic><sup>-/- </sup>(DKO) littermates (provided by Dr. B. De Strooper) were maintained as described [<xref ref-type="bibr" rid="B6">6</xref>]. Transient transfections of cDNAs into cells were performed by DEAE-dextran method (for COS cells), or using lipofectAMINE (Invitrogen) according to manufacturer's instructions [<xref ref-type="bibr" rid="B36">36</xref>]. Retroviral infection was performed as previously described [<xref ref-type="bibr" rid="B37">37</xref>]. To analyze the effect of protease inhibitors (i.e., <italic>N</italic>-[<italic>N</italic>-(3,5-difluorophenacetyl)-L-alanyl]-(<italic>S</italic>)-phenylglycine <italic>t</italic>-butyl ester (DAPT) (kindly provided by Drs. T. Kan and T. Fukuyama, The University of Tokyo [<xref ref-type="bibr" rid="B38">38</xref>]), GM6001 (Chemicon) and epoxomicin (SIGMA)) on the metabolism of ephrin-B and its derivatives, COS cells were cultured in DMEM in the presence of various concentrations of inhibitors for 24 hr and harvested.</p>
      </sec>
      <sec>
        <title>Cell-free Î³-secretase assay</title>
        <p>Membrane pellets were prepared as previously described and stored at -80 degree until use [<xref ref-type="bibr" rid="B39">39</xref>-<xref ref-type="bibr" rid="B42">42</xref>]. All procedures were performed at 4 degree. Membrane pellets were resuspended in 1 Ã Î³ buffer (-C) (10 mM HEPES, pH7.4, 150 mM NaCl, 10% glycerol, 5 mM EDTA, 5 mM 1,10-phenanthroline, 10 Î¼g/ml phosphoramidon, Complete protease inhibitor cocktail (Roche Biochemicals)) with or without indicated inhibitors at 4 or 37 degree for 6â16 hrs. Control reactions were performed in the presence of 1% DMSO. The reaction was stopped by adding the sample buffer and boiling for 2 min. For the detection of <italic>de novo </italic>generated products, samples were separated by SDS-PAGE and analyzed by immunoblotting.</p>
      </sec>
      <sec>
        <title>Reagents and immunochemical analyses</title>
        <p>Antibodies and reagents were purchased from Cell Signaling Technology (anti-myc 9B11), CHEMICON International (anti-lamin A/C), Molecular Probes (Alexa Fluor 488 anti-mouse IgG or Rhodamin-Phalloidin), Roche applied sciences (anti-c-myc 9E10), Santa Cruz (anti-ephrin-B1(C-18)) or SIGMA (anti-Î±-tubulin DM1A). Anti-G1L3 against PS1 loop region was described previously [<xref ref-type="bibr" rid="B40">40</xref>]. Anti-APP antibody C4 is a gift from Dr. Y. Ihara (The University of Tokyo). For preparation of Triton X-100 soluble/insoluble fractions, cells were directly lysed in HEPES buffer containing 1% Triton X-100 and centrifuged at 100,000 Ã g for 1 hr. Membrane preparation, immunoblot or immunocytochemical analyses were performed as previously described [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B39">39</xref>-<xref ref-type="bibr" rid="B42">42</xref>].</p>
      </sec>
      <sec>
        <title>Cell morphology assay</title>
        <p>Transfected COS cells were replated on poly-L-lysine coated coverslips. After staining and mounting, images were taken by CCD camera or FV300 Fluoview conforcal microscopy (Olympus), and processed by Image J software. We defined "cells extending protrusions" by the number (&gt;10) and the length (of the longest process that is longer than 1/3 of the diameter of cell body) of processes.</p>
      </sec>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>Abbreviations: AÎ², amyloid Î²-peptide; AD, Alzheimer's disease; AICD, APP intracellular domain; APP, amyloid-Î² precursor protein; CFNS, craniofrontonasal syndrome; CTF, carboxyl-terminal fragment; DAPT, {<italic>N</italic>-[<italic>N</italic>-(3,5-difluorophenacetyl)-L-alanyl]-<italic>S</italic>-phenylglycine <italic>t</italic>-butyl ester; DKO, <italic>PSen1</italic><sup>-/-</sup><italic>PSen</italic>2<sup>-/-</sup>double knockout mice; ELISA, enzyme-linked immunosorbent assay; FL, full-length; ICD, intracellular domain; MEF. Mouse embryonic fibroblast; NICD, Notch intracellular domain; NTF, amino-terminal fragment; mt, mutant; PMA, phorbol 12-myristate 13-acetate; PS, presenilin; TMD, transmembrane domain; wt, wild-type</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>TT contributed to the conception, design, analysis and interpretation of the data and was responsible for manuscript preparation. ST carried out the experiments described in this article and contributed to the preparation of data for publication. YM interpreted the data and aided in experimental design. TI was responsible for manuscript preparation. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>We thank Drs. B. De Strooper (KU Leuven) for DKO cells, T. Kitamura (The University of Tokyo) for retroviral infection system, T. Kan and T. Fukuyama (The University of Tokyo) for DAPT, H. Bito (The University of Tokyo) for helpful suggestions, and our lab members for helpful discussion and technical assistance. This work was supported by grants-in-aid from the Ministry of Education, Science, Culture and Sports for the 21<sup>st </sup>Century Center of Excellence Program, and by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), Japan. TT and YM are recipients of JSPS Postdoctoral Fellowships for Research Abroad.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>The inhibition of Î³-secretase as a therapeutic approach to Alzheimer's disease</article-title>
          <source>Drug News Perspect</source>
          <year>2004</year>
          <volume>17</volume>
          <fpage>321</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="pmid">15334182</pub-id>
          <pub-id pub-id-type="doi">10.1358/dnp.2004.17.5.829036</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takasugi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tsuruoka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Niimura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Thinakaran</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>The role of presenilin cofactors in the Î³-secretase complex</article-title>
          <source>Nature</source>
          <year>2003</year>
          <volume>422</volume>
          <fpage>438</fpage>
          <lpage>441</lpage>
          <pub-id pub-id-type="pmid">12660785</pub-id>
          <pub-id pub-id-type="doi">10.1038/nature01506</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kopan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ilagan</surname>
              <given-names>MX</given-names>
            </name>
          </person-group>
          <article-title>Î³-Secretase: proteasome of the membrane?</article-title>
          <source>Nat Rev Mol Cell</source>
          <year>2004</year>
          <volume>5</volume>
          <fpage>499</fpage>
          <lpage>504</lpage>
          <pub-id pub-id-type="doi">10.1038/nrm1406</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Strooper</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Annaert</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cupers</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Saftig</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Craessaerts</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mumm</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Schroeter</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Schrijvers</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wolfe</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Goate</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kopan</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A presenilin-1-dependent Î³-secretase-like protease mediates release of Notch intracellular domain</article-title>
          <source>Nature</source>
          <year>1999</year>
          <volume>398</volume>
          <fpage>518</fpage>
          <lpage>522</lpage>
          <pub-id pub-id-type="pmid">10206645</pub-id>
          <pub-id pub-id-type="doi">10.1038/19083</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling</article-title>
          <source>Cytokine Growth Factor Rev</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>337</fpage>
          <lpage>351</lpage>
          <pub-id pub-id-type="pmid">15450250</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.cytogfr.2004.04.001</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herreman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Serneels</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Annaert</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Collen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schoonjans</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>De Strooper</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Total inactivation of Î³-secretase activity in presenilin-deficient embryonic stem cells</article-title>
          <source>Nat Cell Biol</source>
          <year>2000</year>
          <volume>2</volume>
          <fpage>461</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="pmid">10878813</pub-id>
          <pub-id pub-id-type="doi">10.1038/35017105</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blobel</surname>
              <given-names>CP</given-names>
            </name>
          </person-group>
          <article-title>ADAMs: key components in EGFR signalling and development</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>32</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">15688065</pub-id>
          <pub-id pub-id-type="doi">10.1038/nrm1548</pub-id>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yong</surname>
              <given-names>VW</given-names>
            </name>
          </person-group>
          <article-title>Metalloproteinases: Mediators of Pathology and Regeneration in the CNS</article-title>
          <source>Nat Rev Neurosci</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>931</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">16288297</pub-id>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hattori</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Osterfield</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Flanagan</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Regulated cleavage of a contact-mediated axon repellent</article-title>
          <source>Science</source>
          <year>2000</year>
          <volume>289</volume>
          <fpage>1360</fpage>
          <lpage>1365</lpage>
          <pub-id pub-id-type="pmid">10958785</pub-id>
          <pub-id pub-id-type="doi">10.1126/science.289.5483.1360</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Ikeuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gasparini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sisodia</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment Î³. Evidence for distinct mechanisms involved in Î³-secretase processing of the APP and Notch1 transmembrane domains</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>43756</fpage>
          <lpage>43760</lpage>
          <pub-id pub-id-type="pmid">11583985</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.C100410200</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Misonou</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dohmae</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Takio</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ihara</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Distinct intramembrane cleavage of the Î²-amyloid precursor protein family resembling Î³-secretase-like cleavage of Notch</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>35235</fpage>
          <lpage>35238</lpage>
          <pub-id pub-id-type="pmid">11483588</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.C100357200</pub-id>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kopan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schroeter</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Weintraub</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nye</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1996</year>
          <volume>93</volume>
          <fpage>1683</fpage>
          <lpage>1688</lpage>
          <pub-id pub-id-type="pmid">8643690</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.93.4.1683</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ni</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Role of the ErbB-4 carboxyl terminus in Î³-secretase cleavage</article-title>
          <source>J Biol Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>4561</fpage>
          <lpage>4565</lpage>
          <pub-id pub-id-type="pmid">12454007</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M210504200</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kullander</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms and functions of eph and ephrin signaling</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <year>2002</year>
          <volume>3</volume>
          <fpage>475</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="pmid">12094214</pub-id>
          <pub-id pub-id-type="doi">10.1038/nrm856</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Soriano</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Ephrin signaling <italic>in vivo </italic>: look both ways</article-title>
          <source>Dev Dyn</source>
          <year>2005</year>
          <volume>232</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">15580616</pub-id>
          <pub-id pub-id-type="doi">10.1002/dvdy.20200</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cowan</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Henkemeyer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>413</volume>
          <fpage>174</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="pmid">11557983</pub-id>
          <pub-id pub-id-type="doi">10.1038/35093123</pub-id>
        </citation>
      </ref>
      <ref id="B17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Palmer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zimmer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Erdmann</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Eulenburg</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Porthin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Heumann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Deutsch</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase</article-title>
          <source>Mol Cell</source>
          <year>2002</year>
          <volume>9</volume>
          <fpage>725</fpage>
          <lpage>737</lpage>
          <pub-id pub-id-type="pmid">11983165</pub-id>
          <pub-id pub-id-type="doi">10.1016/S1097-2765(02)00488-4</pub-id>
        </citation>
      </ref>
      <ref id="B18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kamata</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Phosphorylation of ephrin-B1 via the interaction with claudin following cell-cell contact formation</article-title>
          <source>EMBO J</source>
          <year>2005</year>
          <volume>24</volume>
          <fpage>3700</fpage>
          <lpage>3711</lpage>
          <pub-id pub-id-type="pmid">16211011</pub-id>
          <pub-id pub-id-type="doi">10.1038/sj.emboj.7600831</pub-id>
        </citation>
      </ref>
      <ref id="B19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zimmer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kohler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>EphB-ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion</article-title>
          <source>Nat Cell Biol</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>869</fpage>
          <lpage>878</lpage>
          <pub-id pub-id-type="pmid">12973358</pub-id>
          <pub-id pub-id-type="doi">10.1038/ncb1045</pub-id>
        </citation>
      </ref>
      <ref id="B20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marston</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Dickinson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nobes</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>Rac-dependent trans-endocytosis of ephrinBs regulates Eph-ephrin contact repulsion</article-title>
          <source>Nat Cell Biol</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>879</fpage>
          <lpage>888</lpage>
          <pub-id pub-id-type="pmid">12973357</pub-id>
          <pub-id pub-id-type="doi">10.1038/ncb1044</pub-id>
        </citation>
      </ref>
      <ref id="B21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jarriault</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Logeat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schroeter</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Kopan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Israel</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Signalling downstream of activated mammalian Notch</article-title>
          <source>Nature</source>
          <year>1995</year>
          <volume>377</volume>
          <fpage>355</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">7566092</pub-id>
          <pub-id pub-id-type="doi">10.1038/377355a0</pub-id>
        </citation>
      </ref>
      <ref id="B22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Sudhof</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60</article-title>
          <source>Science</source>
          <year>2001</year>
          <volume>293</volume>
          <fpage>115</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="pmid">11441186</pub-id>
          <pub-id pub-id-type="doi">10.1126/science.1058783</pub-id>
        </citation>
      </ref>
      <ref id="B23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Komuro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Navin</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Sudol</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus</article-title>
          <source>J Biol Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>33334</fpage>
          <lpage>33341</lpage>
          <pub-id pub-id-type="pmid">12807903</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M305597200</pub-id>
        </citation>
      </ref>
      <ref id="B24">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Tyrosine phosphorylation of the well packed ephrinB cytoplasmic Î²-hairpin for reverse signaling. Structural consequences and binding properties</article-title>
          <source>J Biol Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>24714</fpage>
          <lpage>24720</lpage>
          <pub-id pub-id-type="pmid">12606549</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M210625200</pub-id>
        </citation>
      </ref>
      <ref id="B25">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bong</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Mood</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishimura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Daar</surname>
              <given-names>IO</given-names>
            </name>
          </person-group>
          <article-title>Tyr-298 in ephrinB1 is critical for an interaction with the Grb4 adaptor protein</article-title>
          <source>Biochem J</source>
          <year>2004</year>
          <volume>377</volume>
          <fpage>499</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="pmid">14535844</pub-id>
          <pub-id pub-id-type="doi">10.1042/BJ20031449</pub-id>
        </citation>
      </ref>
      <ref id="B26">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Su</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ni</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Single phosphorylation of Tyr304 in the cytoplasmic tail of ephrin B2 confers high-affinity and bifunctional binding to both the SH2 domain of Grb4 and the PDZ domain of the PDZ-RGS3 protein</article-title>
          <source>Eur J Biochem</source>
          <year>2004</year>
          <volume>271</volume>
          <fpage>1725</fpage>
          <lpage>1736</lpage>
          <pub-id pub-id-type="pmid">15096211</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1432-1033.2004.04078.x</pub-id>
        </citation>
      </ref>
      <ref id="B27">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Twigg</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Kan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Babbs</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bochukova</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Wall</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Morriss-Kay</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Wilkie</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
          <article-title>Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation, cause craniofrontonasal syndrome</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>8652</fpage>
          <lpage>8657</lpage>
          <pub-id pub-id-type="pmid">15166289</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.0402819101</pub-id>
        </citation>
      </ref>
      <ref id="B28">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wieland</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Jakubiczka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Muschke</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thiele</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gerlach</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Wieacker</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome</article-title>
          <source>Am J Hum Genet</source>
          <year>2004</year>
          <volume>74</volume>
          <fpage>1209</fpage>
          <lpage>1215</lpage>
          <pub-id pub-id-type="pmid">15124102</pub-id>
          <pub-id pub-id-type="doi">10.1086/421532</pub-id>
        </citation>
      </ref>
      <ref id="B29">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Compagni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Logan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Control of Skeletal Patterning by EphrinB1-EphB Interactions</article-title>
          <source>Dev Cell</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>217</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="pmid">12919674</pub-id>
          <pub-id pub-id-type="doi">10.1016/S1534-5807(03)00198-9</pub-id>
        </citation>
      </ref>
      <ref id="B30">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aubin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Soriano</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Ephrin-B1 forward and reverse signaling are required during mouse development</article-title>
          <source>Genes Dev</source>
          <year>2004</year>
          <volume>18</volume>
          <fpage>572</fpage>
          <lpage>583</lpage>
          <pub-id pub-id-type="pmid">15037550</pub-id>
          <pub-id pub-id-type="doi">10.1101/gad.1171704</pub-id>
        </citation>
      </ref>
      <ref id="B31">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wieland</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Reardon</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Jakubiczka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Franco</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kress</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Vincent-Delorme</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Thierry</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Konig</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rusu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schweiger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tinschert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wieacker</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Twenty-six novel EFNB1 mutations in familial and sporadic craniofrontonasal syndrome (CFNS)</article-title>
          <source>Hum Mutat</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>113</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="pmid">15959873</pub-id>
          <pub-id pub-id-type="doi">10.1002/humu.20193</pub-id>
        </citation>
      </ref>
      <ref id="B32">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parent</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>NY</given-names>
            </name>
            <name>
              <surname>Taniguchi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Thinakaran</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sisodia</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Presenilin attenuates receptor-mediated signaling and synaptic function</article-title>
          <source>J Neurosci</source>
          <year>2005</year>
          <volume>25</volume>
          <fpage>1540</fpage>
          <lpage>1549</lpage>
          <pub-id pub-id-type="pmid">15703408</pub-id>
          <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3850-04.2005</pub-id>
        </citation>
      </ref>
      <ref id="B33">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>YJ</given-names>
            </name>
          </person-group>
          <article-title>Off limits â integrins holding boundaries in somitogenesis</article-title>
          <source>Trends Cell Biol</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>453</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="pmid">16087338</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.tcb.2005.07.008</pub-id>
        </citation>
      </ref>
      <ref id="B34">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Common mechanisms for boundary formation in somitogenesis and brain development: shaping the 'chic' chick</article-title>
          <source>Int J Dev Biol</source>
          <year>2005</year>
          <volume>49</volume>
          <fpage>221</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="pmid">15906235</pub-id>
          <pub-id pub-id-type="doi">10.1387/ijdb.041960yt</pub-id>
        </citation>
      </ref>
      <ref id="B35">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schumacher</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Maier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sendtner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gessler</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The Notch target genes Hey1 and Hey2 are required for embryonic vascular development</article-title>
          <source>Genes Dev</source>
          <year>2004</year>
          <volume>18</volume>
          <fpage>901</fpage>
          <lpage>911</lpage>
          <pub-id pub-id-type="pmid">15107403</pub-id>
          <pub-id pub-id-type="doi">10.1101/gad.291004</pub-id>
        </citation>
      </ref>
      <ref id="B36">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Saido</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Kume</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shinozaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tokuhiro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Capell</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Grunberg</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haass</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Obata</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid Î² protein ending at the 42nd (or 43rd) residue</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1997</year>
          <volume>94</volume>
          <fpage>2025</fpage>
          <lpage>2030</lpage>
          <pub-id pub-id-type="pmid">9050898</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.94.5.2025</pub-id>
        </citation>
      </ref>
      <ref id="B37">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watanabe</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kitamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Morohashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Pen-2 is incorporated into the Î³-secretase complex through binding to transmembrane domain 4 of presenilin 1</article-title>
          <source>J Biol Chem</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>41967</fpage>
          <lpage>41975</lpage>
          <pub-id pub-id-type="pmid">16234244</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M509066200</pub-id>
        </citation>
      </ref>
      <ref id="B38">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tominari</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rikimaru</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Morohashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Natsugari</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fukuyama</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Parallel synthesis of DAPT derivatives and their Î³-secretase-inhibitory activity</article-title>
          <source>Bioorg Med Chem Lett</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>1983</fpage>
          <lpage>1985</lpage>
          <pub-id pub-id-type="pmid">15050642</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2004.01.067</pub-id>
        </citation>
      </ref>
      <ref id="B39">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tokuhiro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aiba</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Saido</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid Î² peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of AÎ²42</article-title>
          <source>J Biol Chem</source>
          <year>1998</year>
          <volume>273</volume>
          <fpage>21153</fpage>
          <lpage>21160</lpage>
          <pub-id pub-id-type="pmid">9694871</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.273.33.21153</pub-id>
        </citation>
      </ref>
      <ref id="B40">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takikawa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Koyama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Morohashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takasugi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Saido</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>C terminus of presenilin is required for overproduction of amyloidogenic AÎ²42 through stabilization and endoproteolysis of presenilin</article-title>
          <source>J Neurosci</source>
          <year>1999</year>
          <volume>19</volume>
          <fpage>10627</fpage>
          <lpage>10634</lpage>
          <pub-id pub-id-type="pmid">10594046</pub-id>
        </citation>
      </ref>
      <ref id="B41">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwata</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Subcellular compartment and molecular subdomain of Î²-amyloid precursor protein relevant to the AÎ²42-promoting effects of Alzheimer mutant presenilin 2</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>21678</fpage>
          <lpage>21685</lpage>
          <pub-id pub-id-type="pmid">11283011</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M007989200</pub-id>
        </citation>
      </ref>
      <ref id="B42">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morohashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hatano</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ohya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takikawa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Watabiki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takasugi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Imaizumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iwatsubo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4</article-title>
          <source>J Biol Chem</source>
          <year>2002</year>
          <volume>277</volume>
          <fpage>14965</fpage>
          <lpage>14975</lpage>
          <pub-id pub-id-type="pmid">11847232</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M200897200</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>